Pure Global: Brazil's MedTech Fast-Track - The Hidden Cost of ANVISA's New Rules episode artwork

EPISODE · Feb 25, 2026 · 2 MIN

Pure Global: Brazil's MedTech Fast-Track - The Hidden Cost of ANVISA's New Rules

from LATAM MedTech Insights

This week, we dissect a groundbreaking regulatory shift in Latin America's largest market. Brazil's ANVISA has just unveiled a new, accelerated pathway for high-risk medical devices by recognizing approvals from major global agencies, signaling a major push to attract cutting-edge technology. But this speed comes with a hidden cost. The new framework also introduces some of the strictest post-market surveillance demands seen in the region. We explore the critical balance between rapid innovation and patient safety, and what this means for MedTech companies eyeing the Brazilian market. Imagine your company's AI-powered surgical device received FDA approval and can now use a fast-track process for Brazil. You cut your time-to-market by more than a year, but now ANVISA is demanding real-world performance data from Brazilian hospitals to validate its effectiveness locally. How do you leverage the speed of entry without getting buried in this new, intensive compliance burden? Key Takeaways: - What is the AREE reliance pathway and which foreign approvals does ANVISA now recognize? - How does this new rule change the submission strategy for Class III and IV devices in Brazil? - What are the unwritten expectations for post-market surveillance for fast-tracked devices? - How can you prepare a real-world data collection plan for the Brazilian market? - Does this regulatory shift in Brazil signal a wider trend across Latin America? - What are the biggest compliance risks for companies under this new paradigm? - How do you manage technical dossier requirements when leveraging a foreign approval? - What are the key operational costs associated with these new post-market rules? At Pure Global, we specialize in navigating these complex regulatory shifts. Our combination of local expertise and advanced AI tools helps MedTech and IVD companies streamline market access, from initial strategy to post-market surveillance. We turn regulatory hurdles into opportunities for growth. To learn how we can help you succeed in Brazil and over 30 other markets, contact us at [email protected] or visit https://pureglobal.com/.

Episode metadata supplied by the publisher feed · Published Feb 25, 2026

Embed this episode

NOW PLAYING

Pure Global: Brazil's MedTech Fast-Track - The Hidden Cost of ANVISA's New Rules

0:00 2:00

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of LATAM MedTech Insights?

This episode is 2 minutes long.

When was this LATAM MedTech Insights episode published?

This episode was published on February 25, 2026.

Can I download this LATAM MedTech Insights episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!